resulting from these specific translocations encode chimeric transcription factors that cause the transcriptional dysregulation of target genes, whereas others encode chimeric protein tyrosine kinases or autocrine growth factors 5 . Although well studied, the physiological roles of the individual genes in these fusions have seldom been directly linked to their respective sarcoma phenotypes, except perhaps for translocations of the myogenic transcription factor genes paired box 3 (PAX3) and PAX7 with forkhead box O1 (FOXO1) in alveolar rhabdomyosarcomas (ARMS) (discussed below) 6 . In contrast to translocation-associated sarcomas, some karyotypically complex sarcomas can arise from a less aggressive form and pass through discrete stages of progression that are accompanied by increasing genomic complexity. Examples include the progression from atypical lipoma or well-differentiated lipo sarcoma to dedifferentiated liposarcoma [7] [8] [9] , the progression from neurofibroma to malignant peripheral nerve sheath tumour (MPNST) 10, 11 or the progression from enchondroma to chondrosarcoma 12 . Importantly, however, most high-grade karyotypically complex sarcomas present de novo, without antecedent lowergrade lesions. A detailed listing of the genetic abnormalities in sarcomas and their conventional treatment is available elsewhere 4, 13, 14 . We focus here on the core mechanisms of pathogenesis in soft tissue sarcoma, the advanced genomic and functional genetic approaches being used for target discovery in this group of diseases and the novel therapeutic approaches for their treatment.
Translocations
Structural rearrangement that juxtaposes distant genome sequences, resulting in aberrant gene expression or modified regulatory control of a gene (promoter substitution) or the formation of a fusion gene that encodes an aberrant, chimeric protein (gene fusion). Pathognomonic translocations have more than diagnostic use, they are also the defining feature of the given tumour type.
Myogenic
Originating in, or with expression specific to, muscular tissues.
Karyotypically complex
Tumours with a complex karyotype are those with numerical and structural abnormalities affecting multiple chromosomes in the nuclear genome.
Chromothripsis
A neologism coined to describe a proposed single catastrophic remodelling of a chromosome and its accompanying punctuated model of somatic cancer evolution.
Second-generation sequencing
Sequencing methods and associated chemistries that sequence >10 6 nucleic acid fragments in parallel, producing short reads of ~35-400 bases. Used here synonymously with next-generation or massively parallel sequencing.
Molecular mechanisms of sarcomagenesis
The mechanisms that drive human sarcomagenesis fall into three broad categories: transcriptional dysregulation owing to aberrant fusion proteins that result from genomic rearrangements (FIG. 2a) ; somatic mutations in key genes and signalling pathways; and DNA copynumber abnormalities. The epigenetic underpinnings of sarcomagenesis are mostly still to be determined, at least insofar as data on recurrent methylation abnormalities in sarcoma genomes remain limited. Although this Review focuses on these three core oncogenic mechanisms and the distinct therapeutic modalities that may follow, some consideration of the pathogenetic mechanisms relating to chromosome translocations and genomic complexity or instability in sarcomas may be required. The perennial question of how and why translocations arise has been the subject of a recent review 15 . In sarcomas, as in many leukaemias, these seem to be fundamentally random events that become fixed through natural selection within the precursor cell. In silico analysis of sequence and structure indicated that features such as overall gene size, average intron length and the length of the longest intron were all increased in translocation partner genes 16 . Additional factors increase the likelihood of random breaks in two genes leading to an illegitimate recombination event. These include the increased availability of translocation partner genes that is created by open chromatin conformation associated with gene transcription or replication, or the unexpected proximity of some partner genes owing to either the three-dimensional arrangement of chromosomes in the nucleus 17 or coordinated transcription within the same transcriptional hubs. Importantly, so-called 'recombinogenic' DNA sequence elements may be anecdotally involved 18 , but are not more frequent in translocated genes. More recently, the binding of a transcription factor, the androgen receptor (AR), has been implicated more directly in generating DNA strand breaks and consequent gene fusions [19] [20] [21] , an observation so far restricted to prostate cancer, but with intriguing implications for other hormone-driven cancers. Finally, in regard to external risk factors, sarcoma translocations -in particular t(X;18) in synovial sarcoma -may be rarely related to radiotherapy-induced DNA damage [22] [23] [24] . Another aspect of genomic integrity is the mechanisms of telomere maintenance, of which two main types have been described in human tumours -telomerase activation and the alternative lengthening of telomeres (ALT). These seem to differ in frequency between the major genomic classes of sarcomas. A predominance of telomerase activation in the absence of ALT seems to characterize sarcomas with specific chromosome translocations. Alternatively, ALT is frequently seen in sarcomas with nonspecific complex karyotypes 25, 26 , and a connection between ALT and mesenchymal stem cell biology has been proposed 27 . Sarcomas with nonspecific complex karyotypes, but not translocation-associated sarcomas, are also occasionally seen in some hereditary syndromes that are associated with genomic instability, such as Werner's syndrome (caused by mutations in WRN) 28 , Nijmegen breakage syndrome (caused by mutations in nibrin (NBN; also known as NBS1)) 29 and RothmundThomson syndrome (caused by mutations in RecQ protein-like 4 (RECQL4)) 30, 31 . Finally, a recent wholegenome sequencing study has found that some osteosarcomas and chordomas underwent a process termed chromothripsis. Rather than a multistep accumulation of unbalanced rearrangements, this is a single catastrophic genomic instability event that primarily affects a single chromosome 32 . Investigating the pathogenesis of chromothripsis and its occurrence in other sarcomas is of immediate interest.
Transcriptional target dysregulation
Most translocation-associated sarcomas share a common biology of transcriptional target dysregulation. As noted above, most recurrent tumour type-specific translocations in sarcomas produce gene fusions that encode aberrant transcriptional proteins. The general biology of cancer gene fusions has been well reviewed 33 . Likewise, general reviews of translocation-associated sarcomas, including comprehensive listings of recurrent gene fusions in sarcomas, have recently been published 5, 14 ( FIG. 2a) . Here, we limit the discussion to two aspects of transcriptional target gene dysregulation in translocation sarcomas that have been the focus of recent advances: first, the application of genome-wide transcription factor location analyses to comprehensively identify target genes of the fusion proteins, and second, the emerging evidence for aberrant nuclear reprogramming of mesenchymal stem cells in translocation-associated sarcomas. In the therapeutic avenues section below, we also discuss the use of the transcriptional targets of the fusion proteins as therapeutic targets, a third area of recent advances.
Genome-wide approaches to define the target gene repertoires of sarcoma fusions have included chromatin immunoprecipitation (ChIP) coupled to arrays (ChIP-chip), and more recently ChIP coupled to secondgeneration sequencing (ChIP-seq)
. Both methods
At a glance
• Human sarcomas are uncommon malignancies that arise from mesenchymal cell types, have varied genetic origins and are clinically heterogeneous. Many sarcomas arise de novo, driven by a single genetic abnormality, and some are progressive and harbour complex genomes.
• Three core and context-dependent molecular mechanisms drive sarcomagenesis: dysregulation of gene expression by aberrant, chimeric transcription factors generated by specific gene fusions in translocation-associated sarcomas, somatic mutations affecting key signalling pathways and DNA copy-number abnormalities.
• Novel genomic findings from diverse approaches in sarcoma are identifying point mutations that co-occur with translocations, lineage-specific oncogenes, chromosome remodelling events, and both genomic alterations and mutations that alter canonical signalling and differentiation pathways.
• As integrative genomics and massively parallel sequencing increase the pace of discovery for the most common lesions in all but the rarest sarcomas, this necessitates renewed focus on developing in vitro and in vivo sarcoma models for accompanying target discovery and functional annotation of sarcoma genomes with genomics-guided functional genetics.
• Although conventional modalities predominate in sarcoma treatment, new approaches to target aberrant signalling with specific therapies, overcome acquired resistance and target unconventional pathways are rapidly evolving. Ex  tr  as  ke  le  ta  l  m  yx  oi  d  ch  on  dr  os  ar  co  m  a   Welldiffer  entia  ted   lipos  arcom  a   Adipocytic  Chondro-osseous  Fibroblastic or myofibroblastic  Fibrohistiocytic  Nerve sheath  Pericytic  Skeletal muscle  Smooth muscle  Uncertain identify binding sites for the aberrant fusion proteins but, unlike ChIP-chip using commercial promoter arrays, ChIP-seq is not limited to the regions that surround promoters. On integration with expression profiles, it is possible to determine whether the effect of a given fusion protein is predominantly repressing or activating.
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Mapping the genomic binding sites of the PAX3-FOXO1 fusion protein in ARMS cells has shown that binding is associated with the activation of transcription 34 . PAX3-FOXO1 primarily binds to PAX3 sites outside the immediate vicinity of transcription start sites, typically >4 kilobases (kb) downstream. Co-enrichment of target PAX3 motifs with E-box motifs suggests the co-regulation of many target genes by other transcription factors that bind E-boxes 34 . The direct targets identified include myogenic genes, such as myogenic differentiation 1 (MYOD1) and myogenic factor 5 (MYF5), as well as many biologically interesting targets, such as fibroblast growth factor receptor 4 (FGFR4), anaplastic lymphoma receptor tyrosine kinase (ALK), MET, insulin-like growth factor 1 , driver alterations and additional parameters. Branch lengths are determined by nearest neighbour joining of a discretized distance matrix based on the aforementioned variables. Initial branching reflects differences in lineage, with associated lineages appearing closer in distance (such as, skeletal and smooth muscle). Subsequent branching denotes similarity in prognosis, whether they are translocation-associated, and if so, the genes shared among distinct fusions (in this order). Although incomplete, as many subtypes lack sufficient global molecular profiling data on which to base a phylogeny, this initial formulation minimally reflects the relationships among lineage and major molecular lesions in the subtypes. The figure excludes 52 benign types of tumour. Note that the abbreviation MFH represents undifferentiated pleomorphic sarcoma; PNET, primitive neuroectodermal tumour. 
(B.S.T. and S.S., unpublished data). Intrachromosomal rearrangements are shown in orange and interchromosomal rearrangements in dark red; a subset of the interchromosomal rearrangements is reminiscent of some recurrent translocations involving chromosome 12 (chr12) in part a. The left panel shows the pathognomonic chromosome 12q amplification in greater detail. This detailed view indicates a dense network of back-and-forth inverted and non-inverted intrachromosomal rearrangements in three clusters (in grey, purple and blue; for clarity, interchromosomal rearrangements are excluded). The curves reflect rearrangements between two genomic loci, as determined experimentally and computationally. ACTB, actin-β; ALK, anaplastic lymphoma receptor tyrosine kinase; ASPSCR1, alveolar soft-part sarcoma chromosome region candidate 1 (also known as ASPL); ATF1, activating transcription factor 1; CHOP, C/EBP-homologous protein (also known as DDIT3); COL1A1, collagen type Iα1; CREB1, cAMP responsive element binding protein 1; CREB3L, cAMP responsive element binding protein 3-like; EPC1, enhancer of polycomb homologue 1; ETV6, ets variant 6; EWSR1, Ewing sarcoma breakpoint region 1 (which encodes EWS); FLI1, Friend leukaemia virus integration 1; FOXO1, forkhead box O1; FUS, fused in sarcoma; JAZF1, JAZF zinc finger 1; NR4A3, nuclear receptor subfamily 4A3; NTRK3, neurotrophic tyrosine kinase receptor 3; PAX, paired box; PDGFB, platelet-derived growth factor-β; PHF1, PHD finger protein 1; SUZ12, suppressor of zeste 12; TAF15, 68 kDa RNA polymerase II TATA box binding protein-associated factor; TCF12, transcription factor 12; TFE3, transcription factor binding to IGHM enhancer 3; TPM, tropomyosin; WT1, Wilms tumour 1.
Paired-end (or mate-paired) sequencing
A technique whereby a library of genomic DNA or double-stranded cDNA is created and circularized, and then short stretches (35-400 bp) are sequenced from either end of the cleaved product, but not the intervening variable-length fragment (from 200-500 bp to 3-10 kb).
RNA interference
A technique for sequence-specific gene silencing in which small non-coding RNAs (principally microRNAs and small interfering RNAs (siRNAs)) and associated regulatory complexes pair with complementary mRNA targets.
Neuroectodermal
Of the neuroectoderm, including neural crest and neural tube cell types.
receptor (IGF1R) and MYCN, in some cases confirming previous single-gene studies [35] [36] [37] . The role of some of these PAX3-FOXO1 target genes in sarcomagenesis is discussed further below.
In alveolar soft part sarcoma (ASPS), the ASPS locus (ASPL; also known as ASPSCR1) gene fuses with the transcription factor binding to IGHM enhancer 3 (TFE3) gene to form a chimeric protein that retains the TFE3 DNA-binding domain and therefore its CACGTG recognition site. In ChIP-chip studies, we have found that ASPL-TFE3 localization is predictably enriched at this canonical site and is exclusively associated with the activation of target genes, including MET 38 , cytochrome P450 17A1 (CYP17A1) and uridine phosphorylase 1 (UPP1) 39 . A somewhat more complicated picture has emerged for the major Ewing's sarcoma fusion, which involves Ewing sarcoma breakpoint region 1 (EWSR1, which encodes EWS) and Friend leukaemia virus integration 1 (FLI1). Several ChIP data sets have been generated in different Ewing's sarcoma cell lines with endogenous EWSR1-FLI1 fusion, all using the same FLI1 antibody for immunoprecipitation of EWS-FLI1-bound DNA. The numbers of bound genomic regions in such studies have varied widely [40] [41] [42] . ChIP-seq subsequently demonstrated that most of the genomic regions that were bound by EWS-FLI1 were intergenic and that, through the ETS family DNA-binding domain (from FLI1), EWS-FLI1 binds strongly to GGAA microsatellites 40, 41 . Microsatellites containing six or more GGAA repeats (the core ETS domain-binding sequence) are associated with EWS-FLI1 target gene upregulation 40, 42 . These repeats are often more than 200 kb upstream of the target gene transcription start site, suggesting that chromatin looping brings distant regions together in a transcriptional hub to allow EWS-FLI1 to modulate gene expression. As microsatellites are known polymorphic sites, it has been hypothesized that higher repeat content at one or more key target genes may underlie individual or ethnic differences in Ewing's sarcoma susceptibility -for example, its rarity in individuals of African descent 41 . EWS-FLI1 also binds to more conventional, nonrepetitive ETS motifs, and these sites are associated with genes that show either repression or activation of transcription 42 . A subset of EWS-FLI1 target regions shows co-enrichment of sites for other transcription factors: E2F, nuclear respiratory factor 1 (NRF1) and subunits of nuclear transcription factor Y (NFY), raising the possibility of specific cooperative interactions 43 . In general, the combination of genome-wide target gene identification with gene expression data should accelerate the discovery of genes that are crucial to tumour growth and survival in translocation sarcomas. Genes that are found to be directly upregulated by specific aberrant sarcoma fusion proteins can be subjected to focused RNA interference (RNAi)-based screens to identify the genes that are most essential to the sarcoma in question (see Target discovery section below).
Reprogramming. Recent efforts to generate nonembryonic stem cells have renewed interest in nuclear or lineage reprogramming 44, 45 . Understanding reprogramming may also inform our ideas of translocation sarcomas that are driven by aberrant transcription factors. Assigning lineage to translocation sarcomas has proved difficult, as is the case for Ewing's sarcoma, synovial sarcoma, ASPS and others. The cell-of-origin for each of these has long been debated, especially owing to another peculiar clinical feature of these sarcoma types: their occurrence in unusual sites for tumours of bone and soft tissue, such as the kidneys, lungs or pancreas. One explanation for both characteristics is an origin from more than one stem or progenitor cell type or from related precursor cells in different parts of the body, with the similar undifferentiated or aberrantly differentiated phenotypes resulting from nuclear reprogramming by the aberrant transcription factors. For example, it has been shown that EWS-FLI1, the fusion that defines Ewing's sarcoma, can induce neuroectodermal gene expression in heterologous cell types, such as fibroblasts and rhabdomyosarcoma cells 46, 47 . Indeed, this scenario has previously been postulated 48 , and is supported by compelling data from recent studies, although some disagreements remain 49 . Silencing EWS-FLI1 in Ewing's sarcoma cell lines produces an expression profile that is most similar to mesenchymal stem cells (MSCs) or mesenchymal progenitor cells 50, 51 , and these can be subsequently induced to differentiate along adipogenic or osteoblastic lineages 51 . Thus, EWS-FLI1 induces a limited neuroectodermal gene expression programme and imposes a differentiation block on MSCs (or a related cell type 52 ), including a block on osteogenic differentiation by inhibiting runt-related transcription factor 2 (RUNX2) binding to genes that are associated with osteogenic differentiation 53 . In the converse experiment,
Box 1 | Advances in cancer genome and transcriptome characterization
Second-generation sequencing is enabling nucleotide-resolution oncogenomics 188 . Paired-end (or mate-paired) sequencing involves sequencing of short stretches of DNA on both ends of a larger fragment and aligning to the reference genome. Atypically aligned pairs (those with an unexpected position, orientation or separation distance) often reflect genomic rearrangements such as translocations (FIG. 2b) . Paired-end sequencing is therefore a powerful method for ascertaining structural rearrangements and marks the first time that this information has been readily available in an unbiased manner. It is suitable for the detection of rearrangements from variable depth-of-coverage whole-genome sequencing, and its sensitivity increases as the fragment length increases. These methods will help to detect previously unknown driver fusions in sarcomas with highly complex karyotypes. Paired-end sequencing can also be used in RNA sequencing of tumour transcriptomes, as has been done for prostate cancers and other malignancies 189, 190 . To explore the biology of chimeric transcriptional proteins in translocation-associated sarcomas, chromatin immunoprecipitation coupled to sequencing (ChIP-seq) can determine fusion protein location, facilitating target gene discovery. Finally, deep whole-exome and whole-genome sequencing, described in detail elsewhere 188 , have a central place in sarcoma genomics. Exome sequencing first captures and then deeply sequences all protein-coding exons of human genes. By contrast, whole-genome sequencing is unbiased, sequencing all accessible regions in the human genome. Both experiments detect point mutations and small insertions and deletions (indels) in exons, whereas whole-genome sequencing can simultaneously capture genome structure (in paired-end format; described above) and crucially, intergenic variation. Intergenic germline variation or somatic mutations, although currently under-explored, could have an important role in sarcomagenesis. This is typified by the MDM2 SNP309 promoter polymorphism 191 , which, along with MDM2 amplification and TP53 deletion and mutation, represents another (albeit more subtle) mechanism of p53 pathway alteration in a broad range of sarcomas.
EWS-FLI1 expression in human MSCs induces a Ewing's sarcoma-associated gene expression profile, which is especially clear in MSCs that are derived from younger individuals 54, 55 . By contrast, EWS-FLI1 expression in differentiated cell types with an intact ARF-p53 pathway induces apoptosis or growth arrest 46 . In human MSCs, EWS-FLI1 directly upregulates the Polycomb group transcriptional repressor enhancer of zeste homologue 2 (EZH2) 56 and induces expression of embryonic stem cell genes POU5F1 (also known as OCT4), SRY-box 2 (SOX2) and NANOG, at least partly by repressing mir-145 expression 54 . Interestingly, EWSR1 also fuses with POU5F1 itself, albeit rarely, in undifferentiated bone sarcoma 57, 58 , myoepithelial tumours of the soft tissue 59 and certain salivary gland tumours 60 . Synovial sarcomas contain fusions of SS18 (also known as SYT) with either SSX1 or SSX2 (this fusion is referred to as SYT-SSX below). In a striking analogy to the EWS-FLI1 data, synovial sarcoma cell lines also express POU5F1, SOX2 and NANOG, and silencing of SYT-SSX in these cell lines enhances their potential to differentiate along adipogenic, osteoblastic or chondrogenic lineages 61 . The formation of synovial sarcomalike tumours in mice with conditional expression of SYT-SSX2 in myoblasts 62 or other lineages 63 can be interpreted as further evidence of nuclear reprogramming by the fusion protein in a variety of more-or-less committed mesenchymal lineages. Finally, the sarcoma fusions of myxoid liposarcoma (fused in sarcoma (FUS)-C/EBP-homologous protein (CHOP; also known as DDIT3)) and ARMS (PAX3-FOXO1) have also been reported to transform mouse mesenchymal stem or progenitor cells 64, 65 .
Mutations in key genes and signalling pathways
Excluding the gene fusions in translocation sarcomas, few highly recurrent driver genes have been described in sarcoma. The major exception is gastrointestinal stromal tumour (GIST). GIST, one of the more common types of human sarcoma, is characterized by oncogenic mutations in KIT, less often in platelet-derived growth factor receptor-α (PDGFRA) and rarely in BRAF [66] [67] [68] . In fact, the dependence of GIST on constitutively activated KIT and PDGFRα has led to treatment with selective kinase inhibitors (discussed below), representing a paradigm of targeted therapy in solid tumours. Oncogenic mutations occur in several different domains of KIT, and the location affects sensitivity to targeted inhibitors. Levels of KIT are also high in interstitial cells of Cajal, the presumed cell of origin for GIST. Nevertheless, oncogenic KIT mutations in the activation domain (D816V in particular) are also found in tumours of diverse lineages, including mastocytosis, acute myeloid leukaemia and germ cell tumours.
Approximately 10% of adult GISTs lack a KIT or a PDGFRA mutation, and a small subset (<1% of total GIST cases) harbour BRAF V600E mutations 66 (TABLE 1) . In total, approximately 10% of adult and most paediatric 
Carney's triad
A rare syndrome in which there is a coexistence of three distinct tumour types: GIST, extra-adrenal paraganglioma and pulmonary chondromas.
Carney-Stratakis syndrome
Distinct from Carney's triad, and also referred to as the GIST-paraganglioma dyad, a heritable syndrome in which familial mutations are associated with coexisting GIST and paraganglioma, but not pulmonary chondromas.
Neurofibromatosis type I
An autosomal dominant genetic disorder in which tumours arise from nerve tissues and from all neural crest cell types.
Paraganglioma
An uncommon neuroendocrine tumour arising from the sympathetic component of the autonomic nervous system and found predominantly in the abdomen, chest or head and neck region.
Disease-specific survival
Patients with a given diagnosis who do not die of the specified disease in a defined period of time, which excludes patients who died from causes other than the studied disease.
GISTs harbour no mutations in KIT, PDGFRA or BRAF, although KIT pathway activity is high. Among these, paediatric tumours show consistent overexpression of IGF1R mRNA and protein, although the mechanism remains unknown, as no genomic amplifications or activating mutations have been described at the IGF1R locus. In fact, paediatric tumours have mostly diploid genomes with few, if any, DNA copy-number alterations 69 . Therefore, ongoing deep sequencing in paediatric GISTs is being used to identify alternative oncogenic events. A particularly attractive method may be hybrid capture of protein-coding exons followed by second-generation sequencing (exome sequencing
).
Although generally sporadic, GISTs can also present as part of syndromes such as familial GIST, Carney's triad, Carney-Stratakis syndrome and neurofibromatosis type I. In Carney-Stratakis syndrome, which is characterized by the co-occurrence of GIST and paraganglioma, germline mutations in genes encoding subunits of succinate dehydrogenase (SDH) have been identified, as is also the case in familial paraganglioma 70 . Most GISTs that occur in association with neurofibromatosis type I harbour somatic inactivation of the wild-type neurofibromin 1 (NF1) allele, whereas very few have KIT or PDGFRA mutations 71, 72 . A role for tyrosine kinases is also emerging in angiosarcoma, a highly aggressive vascular tumour, in which transcription profiles show striking overexpression of vascular-specific receptor tyrosine kinases, including kinase insert domain receptor (KDR; which encodes vascular endothelial growth factor receptor 2 (VEGFR2)), TIE1, SNF-related kinase (SNRK), TEK and fms-related tyrosine kinase 1 (FLT1) 73 . Sequencing of these five genes has revealed KDR mutations in about 10% of angiosarcoma cases. The VEGFR2-mutant proteins, when expressed in COS-7 cells, showed ligand-independent activation 73 .
A recent large-scale analysis of the genomic landscape of sarcomas that encompassed seven major subtypes (myxoid/round-cell liposarcoma; dedifferentiated liposarcoma; pleomorphic liposarcoma; myxofibrosarcoma; leiomyosarcoma; GIST; and synovial sarcoma) identified frequent mutations in TP53 (which encodes p53), NF1 and PI3K catalytic subunit-α (PIK3CA) 74 . TP53 mutations were identified in 17% of pleomorphic liposarcomas, which is consistent with these mutations occurring frequently in sarcomas with complex karyotypes 75, 76 . By contrast, in translocation-associated sarcomas, secondary genetic alterations, such as TP53 mutations or homozygous deletions of cyclin-dependent kinase inhibitor 2A (CDKN2A), are less common but, when present, are associated with a highly aggressive clinical course 77 . The discovery of PIK3CA mutations in 18% of myxoid/round-cell liposarcomas (TABLE 1) raised the possibility that secondary mutations may cooperate with the FUS-CHOP fusion protein in oncogenesis 74 . Mutations in PIK3CA clustered in the same two 'hot spots' that are observed in epithelial tumours -the helical domain (E542K and E545K) and the kinase domain (H1047L and H1047R). Patients with helical domain mutations had a shorter disease-specific survival and increased phosphorylation of AKT at both CREB-regulated transcription coactivator 2 (CRTC2; also known as TORC2) and pyruvate dehydrogenase kinase 1 (PDK1) phosphorylation sites than patients with wild-type or kinase domain-mutant tumours 74 . Another novel finding is the identification of NF1 alterations (point mutations or deletions) in 10% of myxofibrosarcomas and 8% of pleomorphic liposarcomas 74 (TABLE 1) . NF1 germline and somatic mutations are typically associated with NF1 inactivation in sarcomas in individuals with neurofibromatosis type I, but NF1 mutations had not previously been described in sporadic sarcomas.
Genomic copy-number alterations DNA copy-number alterations are the third core mechanism of sarcomagenesis. Sarcomas span a wide range of complexity among human malignancies in terms of their copy-number alterations 78 . They vary from translocationassociated sarcomas with generally few copy-number alterations, either broad or focal, to karyotypically complex subtypes that are heterogeneous, unstable and profoundly altered in genomic copy number. In addition, a recent high-resolution array-based copy-number analysis revealed a category of sarcomas with intermediate complexity that were mainly characterized by few, but highly recurrent amplifications, as exemplified by dedifferentiated liposarcomas 74 . These and similar genomic data support an alternative sarcoma classification to the one based on low-resolution karyotypes. These three groups are genomically simple sarcomas that are driven by pathognomonic translocations or point mutations, non-translocation-associated sarcomas of intermediate genomic complexity; and highly genomically complex sarcomas. However, some subtypes may not fit so neatly into these broad groups, such as PAX7-FOXO1-positive ARMS. Data from another copy-number analysis show that the third category can be subdivided into sarcomas with few chromosome arm or whole-chromosome gains or losses and sarcoma genomes with a high level of chromosome complexity 79 . The first group, genomically simple sarcomas, harbour characteristic gene fusions or activating mutations that are thought to represent early events in their pathogenesis. However, even these tumours can acquire genomic complexity in advanced stages of disease 80, 81 . Intermediate complexity sarcomas are exemplified by well-differentiated and dedifferentiated liposarcomas, which are mainly driven by chromosome 12 amplifications, often manifesting as double minute chromosomes, ring chromosomes and larger markers 82 (FIG. 2b) . These 12q gains have high prevalence (80-90%), and the coamplified oncogenes cyclin-dependent kinase 4 (CDK4) and MDM2 can serve as confirmatory diagnostic markers 83 and as potential pharmacological targets 74, 84, 85 . The structure, stability and reintegration of these amplicons into liposarcoma genomes can also alter their affect on oncogenic phenotypes 86 . Another gene that is affected by 12q amplification is high mobility group AT-hook 2 (HMGA2), which often loses its 3′ untranslated region (UTR), disrupting microRNA-mediated repression 87 . This genomic remodelling of chromosome 12 is probably the result of progressive rearrangement and amplification in an evolving amplicon rather than of a single catastrophic event, such as the recently proposed chromothripsis that is seen in a subset of osteo sarcomas and chordomas 32 (TABLE 1) . Similar 12q amplifications occur at lower frequencies in other mesenchymal tumours, such as osteosarcomas 88 , as well as several epithelial tumour types 78 . Other notable, albeit less recurrent, amplifications in intermediate-complexity sarcomas occur on 1p and 6q. These amplifications, which seem to be mutually exclusive, span genes in the p38 and JNK pathways of MAPK signalling including, JUN (TABLE 1) on 1p, and TAK1-binding protein 2 (TAB2) and MAP3K5 (also known as ASK1; a kinase upstream of JUN) on 6q 9, [89] [90] [91] . An additional target of genomic amplification is telomerase reverse transcriptase (TERT) on 5p 74 . Some targets of genomic amplification seem to be shared among a subset of both intermediate and highly complex sarcomas, including Yes-associated protein 1 (YAP1) and vestigial-like 3 (VGLL3) on 11q22 and 3p12, respectively 92 . Finally, highly complex sarcomas harbour multiple numerical and structural chromosome aberrations that are reminiscent of the vast majority of epithelial tumours. The molecular classification of these subtypes reflects the varying levels of similarity in their genomic aberrations; some subtypes may be considered as a single entity 93 , while others are distinct 94 . Broad amplifications of several chromosome arms (such as 5p 95 ) often occur in combination with deletions that affect well-established tumour suppressors such as CDKN2A, CDKN2B, PTEN, retinoblastoma 1 (RB1), NF1 and TP53. The affected gene, if not homozygously deleted, often harbours an inactivating mutation in the remaining allele 74 . In fact, several of the products of these genes have a direct role in maintaining chromosome integrity 96, 97 , and their loss of function may be an early event that leads to genomic instability in highly complex sarcomas. In other subtypes, such as leiomyosarcoma, genomic deletions are more common than amplifications 74, 98 . Nevertheless, at least a subset of leiomyosarcomas depends on the specific amplification of myocardin (MYOCD), which encodes a smooth muscle-specific transcriptional co-activator of the serum response factor (SRF) [99] [100] [101] (TABLE 1) . The involvement of MYOCD in smooth muscle differentiation implies that it may serve as a lineage-survival oncogene 102 . Therefore, although systematic catalogues of copy-number alterations point to pathways that are potentially activated in specific subtypes, to precisely delineate the genes that are involved in the events that drive sarcomagenesis it will be essential to annotate genomic characterization with high-throughput functional genetics for target discovery.
Target discovery
Systematic surveys of cancer genomes with integrated genomics have proved to be an effective approach for identifying targetable genetic alterations in specific cancer types. The list of potential targets is expected to grow with the expanded use of second-generation sequencing technologies, which detect not only genome-wide copy-number changes, but also rearrangements and mutations
.
Thus far, large genomic characterization efforts in cancer have mainly focused on epithelial and haematological cancers. Given the need for new therapies for sarcomas, their inclusion in such studies is expected in the near future. For example, The Cancer Genome Atlas (TCGA) project (see Further information) is initiating a comprehensive genomic analysis of dedifferentiated liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma, although this will have to overcome a perennial challenge in sarcoma genomic research -the scarcity of samples. Nevertheless, given the large number of differentiation lineages among diverse sarcomas, a detailed genetic characterization of these tumours is likely to benefit our wider understanding of cancer in general.
Genomics-guided functional genetics.
A gene that is recurrently altered in a sarcoma subtype does not necessarily have a role in cancer initiation or progression. In fact, the identification of recurrent lesions (BOX 2) far outstrips our ability to test their importance. To determine the involvement of a gene in sarcoma biology and to assign it as a therapeutic target, systematic biological validation in genetically defined models must follow. Furthermore, even when a causal role for a given genetic alteration is experimentally supported in a particular cancer type, the crucial downstream targets may remain elusive and so require further functional studies. However, functional studies in sarcoma are hampered by the dearth of such appropriate models. Only limited numbers of human sarcoma cell lines exist, in part because of the rarity of certain diagnoses and the resulting scarcity of samples. Moreover, for each of the subtypes with complex genomes, multiple cell lines are needed to represent the diversity of genetic alterations within that subtype. Several large-scale projects now aim to genetically characterize large numbers of human cancer cell lines and screen these against a range of anticancer therapies to correlate drug sensitivity with genetic markers. Among these are the Cancer Cell Line Encyclopedia (J.B., personal communication) and the Sanger Cancer Cell Line Project 103 , which is assembling approximately 800 cell lines, of which only ten (1.3%) represent complex soft-tissue sarcomas (another 38 represent Ewing's sarcoma or primitive neuroectodermal tumours, rhabdomyosarcoma or osteosarcoma).
There is, therefore, a pressing need to generate cell lines that are representative of diverse sarcoma types, mainly for the subtypes with complex karyotypes. The creation of a sarcoma cell line panel with cytogenetic and genomic profiles that mirror the diversity that is observed in their corresponding tumour types would represent an important step in dissecting the influence of heterogeneity on variability of response to targeted therapies 104 . Such a panel could also drive genomics-guided functional genetics, either with arrayed or pooled loss-of-function RNAi screens 105, 106 , or with gain-of-function ORFeome approaches 107 (FIG. 3) .
Along these lines, we recently sought to functionally annotate the dedifferentiated liposarcoma genome by systematically knocking down genes that are altered by recurrent genomic amplification on 12q and elsewhere. With an arrayed loss-of-function short hairpin RNA (shRNA) screen, we determined which amplified genes are required for cell proliferation and survival 74 . We concentrated on dedifferentiated liposarcomas because the marked homogeneity of their genetic alterations compensates for the low number of cell lines available. Profiling of three dedifferentiated liposarcoma cell lines showed that this small panel captured a substantial number of the molecular abnormalities that are observed in primary tumours. Using these validated cell lines, we identified several genes that are required for cancer cell viability, some of them potentially druggable. For example, the hits included not only CDK4 at 12q14, confirming its importance in this sarcoma, but also aurora kinase A (AURKA) at 20q13, specific inhibitors of which are currently in clinical trials 108 . These studies also provided a setting in which we could address an open question in cancer geneticsnamely, whether focal genomic amplifications contain a single driver gene or, as recently suggested, multiple independent drivers 109 . We found evidence that MDM2 and YEATS4, which are frequently co-amplified with each other (and nearly always in the same tumours with CDK4 amplification) are both drivers 74 . MDM2 is a validated target in this disease, as drugs that inhibit the MDM2-p53 interaction induce apoptosis in dedifferentiated liposarcoma cell lines 84, 85 . Therefore, these data support the concept of multiple driver genes in a single amplicon and hint at a more complex effect of genomic amplification on cancer phenotypes than has previously been understood. Furthermore, co-amplified genes may influence phenotypes that are unrelated to viability, so alternative assays are needed to test their role as oncogenes. Overall, this study design establishes a framework for the systematic genomic and functional genetic characterization of other rare cancers.
In vivo models of sarcoma. In addition to cell lines, several other types of models have been used for sarcoma and are probably similarly adaptable to in vivo functional genetics for target discovery. These include ex vivo cultures of tissue slices that preserve the original tumour microenvironment 110 and low-passage shortterm cultures 111, 112 , both of which are tractable surrogates of primary tumours. Nevertheless, to test novel targeted therapies, it is essential to develop in vivo models of sarcomas. Both subcutaneous and orthotopic xenografts (injecting sarcoma cell lines into immunocompromised mice) have been used to model human sarcomas, but these model systems also have certain limitations. Some genetic abnormalities that are present in primary tumours will not be present or retained in the xenografts, and, conversely, serial passaging can introduce additional alterations that do not reflect the primary tumours. Indeed, many treatments that initially showed promise in these models have not successfully translated to the clinic. To overcome these limitations, researchers are attempting to create panels of xenografts directly from primary tumour tissues that represent several sarcoma subtypes 113 . An alternative to xenografts is to genetically engineer animal models that reproduce the characteristics of human tumours, but this presents specific challenges. For mouse models of translocation-associated sarcomas, the challenge is to express the fusion oncogene in the correct lineage and stage of development. For mouse models of karyotypically complex sarcomas, the challenge is to express genuine alterations in an appropriate combination. For example, in leiomyosarcoma, the most prominent genetic alteration is chromosome 10 deletions that affect PTEN, but this may be a secondary alteration. Nonetheless, this was modelled by genetically inactivating Pten in the smooth muscle cells of mice, which led to leiomyosarcomagenesis 114 . Another recent mouse model introduced oncogenic Kras and mutant Trp53 into the muscle of mice; these changes were sufficient to generate high-grade sarcomas with myofibroblastic differentiation 115 , but KRAS is rarely mutated in human sarcomas. Sarcomas with simple karyotypes that have been success fully modelled are synovial sarcoma 62, 63 , ARMS 116 , myxoid liposarcoma 117 and GIST 118, 119 . Nevertheless, in one model of synovial sarcoma 62 , the SYT-SSX fusion oncogene was targeted to the myogenic lineage, a lineage that is inconsistent with conventional pathological data on this sarcoma.
These and other sarcoma models may reveal the specific roles of genes that are altered in primary tumours and might allow the identification of secondary genetic or phenotypic events that are required for sarcoma progression and/or metastasis (FIG. 3) . Engineered animal models may also be adapted to in vivo RNAi screens, as has been demonstrated in models of hepatocellular carcinoma and lymphoma [120] [121] [122] (FIG. 3) . This approach to exploring gene function would be especially powerful in soft-tissue sarcomas with complex genotypes and numerous chromosome aberrations. Genetically engineered animal models can also be used for diagnostic or prognostic biomarker discovery, drug testing and
Box 2 | Identifying candidate driver alterations in noisy cancer genomes
Over the course of their somatic evolution, cancer genomes can acquire an array of abnormalities. These alterations either confer a clonal growth advantage to the cell (driver) or are acquired stochastically, but are biologically neutral (passenger). The need to distinguish between these two alteration types in increasingly complex genomic data has driven the development of robust and statistically principled computational methodologies. Alteration type-specific methods have particularly focused on DNA copy-number alterations (CNAs), one of the most common somatic genetic events not only in karyotypically complex sarcomas, but also in the genomes of epithelial cancers. Two such methods, Genomic Identification of Significant Targets in Cancer (GISTIC) 192 and RAE 193 , not only assign a significance to candidate driver alterations emerging from a background of random, passenger abnormalities using their pattern of recurrence, amplitude and extent, but also assign to individual tumours the set of CNAs they have undergone. The outputs of these computational methods can be used in studies of clinical associations, analyses of aberrant pathway activity, integrated with orthogonal data, or used to populate large-scale functional genetic screens. Alternatively, other methods, such as iCluster 194 and Copy Number and Expression in Cancer (CONEXIC) 195 identify putative driver alterations by integrating multiple high-throughput data types (such as, expression and copy number). Nature Reviews | Cancer drug resistance studies 123 . Indeed, the combination of sarcoma tumour profiles, sarcoma model systems that faithfully represent the alterations that are characteristic of their tumour type, and in vitro and in vivo functional genetics is a powerful approach to target discovery that is also being applied to other cancers by the US National Cancer Institute's Cancer Target Discovery and Development Network 124 .
Therapeutic avenues
Despite the many advances in identifying genetic abnormalities in sarcoma and in elucidating their function, cytotoxic chemotherapy remains the standard of care for most locally advanced and metastatic sarcomas. However, complete surgical resection is the best hope for cure, and few patients with unresectable disease are curable by cytotoxic chemotherapy. Indeed, there are currently few specific genetic lesions in sarcoma that are direct targets of therapy, unlike epithelial cancers that harbour mutations that confer sensitivity to targeted inhibitors 125 . The exception among sarcomas is GIST, in which the KIT kinase inhibitor imatinib achieves a partial response or stable disease in approximately 80% of patients with advanced or metastatic GIST, often within days, with some patients now on therapy for 10 years 126 . These responses to imatinib depend, however, on the specific site of mutation; tumours with activation loop mutations are generally insensitive. The response to imatinib has also been disappointing in patients with wild-type KIT and PDGFRA genotypes, despite KIT pathway activation. These findings lend support to a genotype-driven paradigm of kinase inhibition. This paradigm may apply across tumours of diverse histologies that share addiction to a particular mutated kinase. For example, the recent success of RAF inhibitors in BRAF-V600E-mutant melanoma suggests that responses may be elicited in other tumour types with a dependence on oncogenic RAF 127, 128 , a possible therapeutic option for the approximately 1% of adult patients with GIST with BRAF-V600E mutation 66 . GIST notwithstanding, other common sarcomas have shown very little sensitivity to existing tyrosine kinase inhibitors (TKIs), including leiomyosarcoma, high-grade undifferentiated pleomorphic sarcoma (formerly termed malignant fibrous histiocytoma) and well-differentiated or dedifferentiated liposarcoma 129, 130 . Nevertheless, kinase-directed agents have produced responses in certain translocation-associated sarcomas 130, 131 (TABLE 2) .
Among these are responses to imatinib in dermatofibrosarcoma protuberans (DFSP) with collagen Iα1 (COL1A1)-platelet-derived growth factor-β (PDGFB) fusions, as well as in giant-cell tumours of the tendon sheath with collagen VIα3 (COL6A3)-colony-stimulating factor 1 (CSF1) fusions 132, 133 . MET inhibitor responses are seen in ASPS and clear-cell sarcomas with ASPL-TFE3 and EWS-activating transcription factor 1 (ATF1) fusions, respectively 38, 134, 135 . ALK inhibitor responses are seen in inflammatory myofibroblastic tumours with ALK fusions 136 ; and IGF1R antibody responses are seen in Ewing's sarcoma with EWS-FLI1 or EWS-ERG fusions [137] [138] [139] . However, in none of these instances have clinical responses proved to be as durable as the responses observed in patients with GIST that are treated with imatinib or other TKIs. In addition, patients with Ewing's sarcoma have an approximately 10-15% response rate to anti-IGF1R therapy, but in these tumours, and in High-throughput integrative genomics, increasingly dominated by second-generation sequencing, identifies abnormalities of sequence, structure, expression or copy number (a) in sarcoma genomes (notwithstanding epigenetic modification). In parallel, model systems (cultured cells, animal models or tissue slices) need to be generated from human tumours (b) and similarly be genomically profiled to confirm that they represent primary tumours in the retention of driver alterations (c). From tumour profiles, computational methodologies (dashed arrow) analyse the patterns of recurrence to distinguish likely driver from passenger alterations (d)
. These models can then be subjected to high-throughput functional genetic analyses, including both gain-of-function approaches (such as open reading frame (ORF) overexpression with pLX-Blast-V5 or similar cDNA expression vectors) and loss-of-function approaches (such as RNA interference using pLKO1-puro or similar short hairpin RNA (shRNA) plasmids) (e). These approaches can be applied either to all genes (to identify genotype-selective targets from those that are not) or to those identified by the integrative genomic and statistical methods. The readouts of these high-throughput methods, be it fluorescence, barcode arrays, or sequence read counts, provide data on one of a large number of possible phenotypes and can be analysed (f) to identify genotype-dependent vulnerabilities in sarcoma cells, identifying targets that can be validated in orthogonal models (g), a subset of which may be suitable for therapeutic intervention. This model of genomics-driven functional genetics focuses on rapid functional annotation of cancer genomes. GEMM, genetically engineered mouse model; indel, insertion/deletion.
angiosarcomas, preclinical evidence would have predicted a greater response rate 131, 140, 141 . The reason for this discrepancy is unknown, although perhaps only a small proportion of patients have overtly IGF1R-dependent tumours that are possibly driven by high serum IGF1 levels, as has been proposed in non-small-cell lung cancer 142 . Among some less common sarcoma subtypes, several targeted agents seem to be active (TABLE 2) . In addition, the identification of moderately or highly prevalent genetic abnormalities in some subtypes has suggested new possibilities for therapy. VEGFR-directed therapies such as bevacizumab and sorafenib are associated with approximately 15% response rates in primary and ionizing radiation-induced angiosarcoma 129, 143 , with these responses perhaps associated most closely with KDR mutation 73 . ASPS tumours are sensitive to VEGF-directed therapy such as cediranib or sunitinib 144, 145 . On the basis of the reduced expression of tuberin (TSC2), perivascular epithelioid cell tumours (PEComas) and related conditions such as lymphangioleiomyomatosis and angiomyolipoma respond to mTOR inhibition [146] [147] [148] . As NF1 inactivation leads to aberrant MAPK and mTOR pathway activity 149, 150 , the NF1 mutations and genomic deletions that have recently been observed in pleomorphic liposarcomas and myxofibrosarcomas 74 may identify a broader range of patients who might respond to either RAF-MEK inhibitors or rapamycin and its analogues (rapalogues). In fact, using rapalogues in several complex subtypes could be justified on the basis of highly prevalent PTEN deletions, as in leiomyosarcoma 114 . However, preliminary results of a Phase III study of the mTOR inhibitor ridaforolimus indicated that progression-free survival was extended by only 3.1 weeks after the completion of cytotoxic chemotherapy compared with the control group, suggesting limited utility of mTOR inhibitors in patients with sarcoma who are not first selected on the basis of their genomic abnormalities. The finding of frequent PIK3CA mutations in myxoid/round-cell liposarcoma 74 (TABLE 1) suggests that at least this molecular subset of patients might benefit from PI3K inhibitors; this is currently being tested in clinical trials.
Finally, and although it is not strictly a targeted chemo therapeutic agent, trabectedin, a DNA minor groove-binding drug that is now approved in Europe for use in sarcomas, shows a substantial response rate in myxoid/round cell liposarcoma with FUS-CHOP and EWSR1-CHOP fusions and perhaps in additional translocation-associated sarcomas 151, 152 . Although the precise function of trabectedin in sarcomas is unclear, it seems to involve alterations in transcription downstream of histone and transcription factor binding 153 . ALK, anaplastic lymphoma receptor tyrosine kinase; ASPL, alveolar soft part sarcoma locus; ATF1, activating transcription factor 1; COL1A1, collagen type Iα1; COL6A3, collagen type VIα3; CSF1, colony-stimulating factor 1; EWS, Ewing sarcoma breakpoint region 1; FLI1, Friend leukaemia virus integration 1; GIST, gastrointestinal stromal tumour; IGF, insulin-like growth factor; IGF1R, insulin-like growth factor 1 receptor; PDGFR, platelet-derived growth factor receptor; PEComa, perivascular epithelioid cell tumour; TFE3, transcription factor binding to IGHM enhancer 3; TSC2, tuberin; VEGFR, vascular endothelial growth factor receptor. *Dasatinib and sorafenib are also indicated for KIT-mutant GIST.
Trabectedin sensitizes cancer cell lines to FAS-mediated cell death 154 , and sarcomas with intact nucleotide excision repair (NER) seem to be more sensitive to the drug than those with dysfunctional NER 155 . Acquired and adaptive resistance. Malignancies, both epithelial and mesenchymal in origin, have remarkable similarity in their mechanisms of acquired and adaptive drug resistance. Resistance to TKIs is frequently acquired through second-site mutations, as in KITmutant GIST [156] [157] [158] . For patients with metastatic disease, the median time to progression on first-line imatinib therapy is approximately 2 years. Here, the nature of secondary KIT mutations depends on the location of the primary KIT mutation. For example, GISTs harbouring the more common and imatinib-sensitive KIT exon 11 mutation tend to become resistant by acquiring a second-site KIT mutation in exon 11 rather than in exon 9. Resistance to broad-based second-line KIT inhibitors (sunitinib), arising on average within ~6 months, can also develop through selection for double KIT-mutant resistant clones 159 . Another mechanism of resistance may involve alternative oncogenic pathways or rewiring of signalling networks, as experimental evidence suggests is the case for IGF1R inhibitors in rhabdomyosarcomas and Ewing's sarcoma cell lines 160, 161 . This adaptive resistance is consistent with the lack of IGF1R mutations observed in cancer types in which these therapies are active.
To circumvent these mechanisms of drug resistance, additional novel agents and strategies will be required. A strategy currently being used for imatinib-resistant chronic myelogenous leukaemia is the development of second-generation or third-generation inhibitors with kinase-binding affinity or binding to sites other than the kinase domain itself 162 . The newer generation KIT inhibitors that are in preclinical development bind to the switch pocket domain of the protein, overcoming the resistance that is mediated by most combinations of KIT mutations observed in clinical samples 163 . However, the complexity of polyclonal resistance in patients with imatinib-resistant GIST suggests that a single nextgeneration drug is unlikely to inhibit all mutant clones in a given patient, and broader therapeutic strategies need to be considered. Strategies being examined in clinical trials include drug combinations that block specific heterodimerization of receptor tyrosine kinases or multiple levels in a single signalling pathway. One such example is an inhibitor of cell division cycle 37 (CDC37), a protein that links KIT to the chaperone heat shock protein 90 (HSP90); this inhibitor may potentiate KIT degradation without the potential toxicity that is inherent to inhibiting too many HSP90 client proteins [164] [165] [166] . Other approaches warrant study, including polypharmacology (the simultaneous inhibition of multiple targets) 167 .
Transcriptional target genes as a therapeutic target.
Considering the therapeutic strategies aimed at the aberrant transcriptional proteins that drive translocation sarcomas, we note that transcription factors are considered poorly druggable because their proteinprotein and protein-DNA interactions have historically been difficult to inhibit with small molecules. This view may be changing 168, 169 , and, in sarcoma, a notable example exists with a small molecule that disrupts a crucial interaction of the EWS-FLI1 protein with RNA helicase A in Ewing's sarcoma 170 . Nevertheless, the most promising current approach to discovering therapeutic targets in translocation sarcomas is identifying the targets of the chimeric transcription factor and focusing on those that encode known drug targets. The receptor tyrosine kinase MET has emerged as such a target in several sarcomas. MET is a direct transcriptional target of ASPL-TFE3 in ASPS 38 , and apparently also of PAX3-FOXO1 in ARMS 36, 171 . In clear-cell sarcoma, EWS-ATF1 transactivates microphthalmia-associated transcription factor (MITF), which in turn directly activates MET transcription 134, 172 . The fact that these fusion proteins upregulate MET has justified a Phase II multi-institutional study of the MET inhibitor ARQ197 in patients with advanced clear cell sarcoma and ASPS. The transcriptional targets of the Ewing's sarcoma fusion protein EWS-FLI1 seem to affect multiple pathways, including NOTCH 173 , Hedgehog-GLI 174, 175 , WNT-β-catenin 176 , transforming growth factor-β (TGFβ) 177, 178 and possibly IGF1R 179 . The IGF1R pathway may be dysregulated by EWS-FLI1 at several levels, including IGF1 upregulation and IGF binding protein 3 (IGFBP3) repression 138, 180, 181 . The IGF1R pathway is also transcriptionally upregulated by the PAX3-FOXO1 fusion in ARMS 34, 35 . These findings have in part provided the rationale for trials of IGF1R inhibitors in these sarcomas 141, 182, 183 . Finally, in myxoid/round cell liposarcoma, the FUS-CHOP fusion oncoprotein forms a complex with nuclear factor-κB inhibitor ζ (NF-κBIζ) at target promoters, thereby upregulating NF-κB target genes 184 . Thus, NF-κB pathway inhibition, which reduces the viability of myxoid liposarcoma cell lines 185 , may represent a new therapeutic option in this translocation sarcoma.
Alternative therapeutic approaches. The insensitivity of many sarcomas to existing systemic therapy is driving the exploration of agents that are aimed at new types of targets. Among these are HSP90 inhibitors, which have been studied in GISTs but not in other sarcomas. Other novel targets include BCL-2, phosphatases that are involved in feedback control of oncogenic pathways and key mediators of epigenetic regulation, including histone deacetylases, histone acetyltransferases and DNA methyltransferases. Epigenetic approaches may lead to the re-expression of pro-apoptotic molecules, which may induce apoptosis or senescence or which may render sarcomas sensitive to other agents, although this is speculation at present. Similarly, cell cycle regulators including CDK4 and CDK6 (REF. 186 ) have proved to be attractive but refractory targets, whereas strategies to target components of the mitotic apparatus such as aurora kinases are actively under development. Targeting the p53-MDM2 pathway with nutlins is promising in tumours with MDM2 amplification (FIG. 4) , internationalscale cooperative studies are paramount, as is ensuring that patients with sarcomas are included, along with more common cancers, in clinical trials of biologically relevant agents.
Future directions
The diagnosis and treatment of patients with sarcoma is entering a period of rapid evolution. The dramatic drop in the cost of personal genome sequencing may alter the clinical and therapeutic course for patients with sarcoma, as it is becoming technically possible to guide patient care by the analysis of the patient's cancer and normal genome sequences, and this may also soon become practically feasible 187 . Over the next few years, the catalogue of mutations that drive all but the least common diseases will become known, thanks to large-scale efforts, such as TCGA and the International Cancer Genome Consortium, as well as others. To prevent sarcomas from lagging behind epithelial cancers in target discovery, it will be crucial to develop robust models of disease to allow the rapid functional annotation of the genetic abnormalities that are identified from both research and clinical sequencing. 
